Name: Name:7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
Brand: AABLOCKS
SKU: AA003A9C
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA003A9C

Chemical Name: 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

CAS Number: 1211441-98-3

Molecular Formula: C23H30N8O

Molecular Weight: 434.5373

MDL Number: MFCD27976795

SMILES: CN(C(=O)c1cc2c(n1C1CCCC1)nc(nc2)Nc1ccc(cn1)N1CCNCC1)C

Properties

Complexity: 636

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 32

Hydrogen Bond Acceptor Count: 7

Hydrogen Bond Donor Count: 2

Isotope Atom Count: 0

Rotatable Bond Count: 5

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 2.2

Downstream Synthesis Route

1211441-98-3

108-24-7

1211440-39-9

[1]Patent:WO2010/20675,2010,A1.Locationinpatent:Page/Pagecolumn107;108

1211441-98-3

4023-34-1

1211440-87-7

[1]Patent:WO2010/20675,2010,A1.Locationinpatent:Page/Pagecolumn108

74-96-4

1211441-98-3

1211442-07-7

[1]Patent:WO2010/20675,2010,A1.Locationinpatent:Page/Pagecolumn93

1211441-98-3

15448-47-2

1211441-56-3

[1]Patent:WO2010/20675,2010,A1.Locationinpatent:Page/Pagecolumn95;96

Literature fold

Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

Journal: Toxicology letters20180701

Title: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Journal: The Lancet. Oncology20180701

Title: A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20161201

Title: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Journal: The New England journal of medicine20161103

Title: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20131115

Title: A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.

Journal: Cancer biology & therapy20130701

Title: The requirement for cyclin D function in tumor maintenance.

Journal: Cancer cell20121016

Title: Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

Journal: Cancer cell20121016

Title: Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

Journal: Cell cycle (Georgetown, Tex.)20120715

Title: Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.

Journal: Biochimica et biophysica acta20110801

Title: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Journal: Cancer cell20100713

Title: The landscape of somatic copy-number alteration across human cancers.

Journal: Nature20100218

Title: Requirement for CDK4 kinase function in breast cancer.

Journal: Cancer cell20060101

Title: VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.

Title: Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.

1211441-98-3 | 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide